Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.53 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PRNP | P04156 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710402 | 0.93 | CDK1 (0.74) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL13999523 | 0.86 | HTR1A (0.76) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL12871542 | 0.85 | KDM4E (0.61) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1695386 | 0.85 | KDM4E (0.61) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1147601 | 0.85 | KDM4E (0.84) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1147600 | 0.84 | KDM4E (0.82) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1147663 | 0.84 | KDM4E (0.82) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL12871599 | 0.84 | KDM4E (0.60) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1147009 | 0.83 | CDK1 (0.81) | CDK1KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL1147537 | 0.82 | CDK1 (0.80) | CDK1KDM4ELMNAHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| EP-2694086-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | The Texas A&M University System (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138708-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1261340-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RES GROUP LLC (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| JP-2004500331-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
| WO-2026102333-A1 | METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | Atrium Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | CDK1 1123/4885KDM4E 1629/4885LMNA 3780/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | CDK1 2766/4885KDM4E 1405/4885LMNA 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.